Ipsen – Half year statement – 2023 06 30
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Paris (France), July 10, 2023 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2023, the following resources were included to the dedicated liquidity account:
- 17,348 shares
- €3,350,842.85
It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between January 1st, 2023 and June 30, 2023 have been executed:
- 3,153 purchase transactions
- 2,820 sell transactions
Under the same period, the volumes traded represented:
- 360,894 shares and €38,313,096.35 to the purchase
- 367,615 shares and €39,180,843.15 to the sell
Attachment

Ipsen – Half year statement – 2023 06 30
Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF
Paris (France), July 10, 2023 – Under the liquidity agreement entrusted by IPSEN SA to NATIXIS ODDO BHF, as of June 30, 2023, the following resources were included to the dedicated liquidity account:
- 17,348 shares
- €3,350,842.85
It is reminded that as of the date of the signature of the agreement, the following assets were allocated to the liquidity account:
- 12,751 shares
- €3,137,934.80
Between January 1st, 2023 and June 30, 2023 have been executed:
- 3,153 purchase transactions
- 2,820 sell transactions
Under the same period, the volumes traded represented:
- 360,894 shares and €38,313,096.35 to the purchase
- 367,615 shares and €39,180,843.15 to the sell
Attachment

Related Press Releases
Ipsen appoints Michelle C. Werner as EVP, President of North...
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in...
Ipsen confirms U.S. FDA grants priority review for New Drug...
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen – Monthly information relative to the total number of...
IPSEN – Buy-back programme – Art 5 of MAR –...
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE...
Ipsen announces positive outcome of FDA Advisory Committee on investigational...
IPSEN – Buy-back programme – Art 5 of MAR –...